Trial Profile
Impact of evolocumab on periprocedural microvascular damage in patients undergoing percutaneous coronary intervention (PCI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms EVOCATION; EVOLUTION Trial
- 13 May 2022 Status changed from not yet recruiting to completed as per results presented at the 71st Annual Scientific Session of the American College of Cardiology
- 04 Apr 2022 Study design presented at the 71st Annual Scientific Session of the American College of Cardiology
- 03 Apr 2018 New trial record